Du är här

2016-02-10

DBV Technologies: DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting

---------------------------------------
| Press Release |
| |
|Montrouge, France, February 10, 2016 |
---------------------------------------

DBV Technologies to Present New Data at the 2016 AAAAI Annual Meeting2-Year Follow-Up of Clinical Data Further Support Viaskin®Peanut's Efficacy
and Safety Profile

Research Results Provide Additional Insights into EPIT®'s Differentiated
Mechanism of Action and Highlight the Broad Viaskin Platform

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that nine abstracts on Epicutaneous Immunotherapy (EPIT) have been selected
for presentation at the 2016 American Academy of Allergy, Asthma&Immunology
(AAAAI) Annual Meeting in Los Angeles, CA, March 4-7, 2016. All abstracts are
available online athttp://annualmeeting.aaaai.org/, and will also be
published in a supplement to the FebruaryJournal of Allergy and Clinical
Immunology (JACI
)http://www.jacionline.org/.

In addition to the clinical and scientific publications which will be
presented as part of the 2016 AAAAI Annual meeting by DBV:

* On Friday, March 4, two additional oral presentations featuring new EPIT
data will be highlighted during theAllergen Immunotherapy, Today and
Tomorrow: Session II. Immunotherapy with Food Allergens educational
session.
* On Sunday, March 6, DBV Technologies will host a Symposium, "Epicutaneous
Immunotherapy - A Novel Pathway for The Treatment of Food Allergies " from
6:30 - 8:30 PM at the Diamond Ballroom Level, Salon 4 at the JW Marriott
Los Angeles L.A. LIVE. The Symposium will be broadcasted live and archived
online
athttp://www.dbv-technologies.com/en/news-events/scientific-congresses.

"We are extremely proud of the breadth and quality of results we will be
presenting at AAAAI this year
," saidDr.
Pierre-Henri Benhamou
, Chairman and Chief Executive Officer of DBV Technologies. "We are committed
to accelerating therapeutic innovation in food allergy
diseases, for which there are no approved treatments. Our AAAAI data
continues to demonstrate that DBV combines deep science and robust clinical
development in order to bring safe, effective and convenient therapies to our
patients.
"
Presentations in Peanut Allergy

Clinical Data

* "Enhanced Efficacy and Confirmed Safety of a Two-Year Epicutaneous
Immunotherapy (EPIT) Treatment of Peanut Allergy with Viaskin® Peanut: The
Continuation of the VIPES Phase IIb Randomized Controlled Trial" will be
presented by Dr. Hugh Sampson, Chief Scientific Officer, DBV Technologies.
After previously announcing that the 12-month VIPES trial met its primary
endpoint, two-year follow up data showed increasing response rates with
Viaskin Peanut over time. The response rates after 24 months of EPIT with
Viaskin Peanut 250 µg were 69.7% overall and 80.0% in children 6-11 years,
compared to 50% overall and 53.6% in children after 12 months. Adolescents
and adults treated remained stable. * Oral Presentation * Session Number:
3611 * Poster Number: L59 * Session Title: Clinical/Translational Sciences
* Date/Time: Sunday, March 6 / 2:00 PM to 3:15 PM

FARRP (Food Allergy Research&Resource Program
) Presentation

* "Quantitative Assessment of the Safety Benefits Associated with Increasing
Clinical Peanut Thresholds through Immunotherapy" will be presented by Dr.
Joe Baumert, Associate Professor in the University of Nebraska, Department
of Food Science and Technology. Using risk modeling, this study was
designed to determine the level of protection against accidental exposure
to undeclared peanut residue in food after partial desensitization. Dr.
Baumert concluded that reaching a threshold dose of 300 mg peanut protein
would be a key milestone in the treatment of highly peanut-sensitive
individuals. * Poster Session * Session: 3206 * Poster Number: 417 *
Session Title: Food Allergy: Diagnosis and Management * Date/Time: Sunday,
March 6 / 9:45 AM to 10:45 AM

CoFAR (Consortium of Food Allergy Research
) Presentations
· "Epicutaneous Peanut to Treat Peanut Allergy"

will be presented by Dr. Stacie Jones, Chair of National Institute of Allergy
and Infectious Diseases' Consortium of Food Allergy Research (CoFAR).
o Oral Presentation
o Session Number:
1201

o Session Title:
Allergen Immunotherapy, Today and Tomorrow: Session II. Immunotherapy with
Food Allergens

o Date/Time:
Friday, March 4 / 10:00 AM to 10:30 AM

· "Insights from New Mechanistic Studies on Food Allergy"

will be presented by Dr. Cecilia Berin, Associate Professor Pediatrics, Mount
Sinai Hospital in New York, NY.
o Oral Presentation
o Session Number:
1201

o Session Title:
Allergen Immunotherapy, Today and Tomorrow: Session II. Immunotherapy with
Food Allergens

o Date/Time: Friday,
March 4 / 10:30 AM to 11:00 AM

Clinical Data in Cow's Milk Allergy

· "Safety of Viaskin Milk Epicutaneous Immunotherapy (EPIT) in
IgE-Mediated
Cow's Milk Allergy (CMA) in Children (MILES Study)"

will be presented by Dr. Karine Rutault, DBV Technologies. In Part A of this
study, 18 children ages 2-17 were enrolled to explore the safety of three
different doses of Viaskin Milk (150 µg, 300 µg or 500 µg) when compared to
placebo. No safety concerns were observed.
o Poster Session
o Session Number:
3206

o Poster Number:
437

o Session Title:
Food Allergy: Diagnosis and Management

o Date/Time:
Sunday, March 6 / 9:45 AM to 10:45 AM

Presentation on the Use of the Platform in Hemophilia A

* "Epicutaneous Immunotherapy Using Plasma-Derived Factor VIII Reduces the
Inhibitory Immune Response to Therapeutic Factor VIII in Experimental
Hemophilia A" will be presented by Dr. Sebastien Lacroix-Desmazes, Director
of Research, INSERM, Immunopathology and Therapeutic Immuno-Intervention
Section. In this study, epicutaneous exposure to pdFVIII of hemophilic mice
sensitized to FVIII was observed to reduce immune response to therapeutic
FVIII during replacement therapy. * Oral Presentation * Session Number:
2602 * Poster Number: 289 * Session Title: From the Bench to the Bedside,
When Clinical and Basic Science Research Advance Clinical Care * Date/Time:
Saturday, March 5 / 2:30 PM to 2:45 PM

Research Presentations on EPIT's Mechanism of Action

* "EPIT Prevents from the Induction of Anaphylaxis to Further Allergens: Role
of Naïve Tregs" will be presented by Dr. Lucie Mondoulet, Deputy Chief
Scientific Officer at DBV Technologies. This preclinical study examines the
role of Regulatory T Cells (Tregs) during allergen immunotherapy with EPIT.
Dr. Mondoulet observed that naive Tregs, induced by EPIT, seem to confer
protection against sensitization to further allergens. * Poster Session *
Session Number: 2210 * Poster Number: 195 * Session Title: Immunotherapy,
Anaphylaxis * Date/Time: Saturday, March 5 / 9:45 AM to 10:45 AM
* "No Impact of Filaggrin Deficiency on EPIT Efficacy in a Murine Model" will
be presented by Dr. Sophie Wavrin, DBV Technologies. Results of this
preclinical study show that EPIT remains efficacious and safe in the
presence of Filaggrin polymorphism or mutations. * Poster Session * Session
Number: 3206 * Poster Number: 438 * Session Title: Food Allergy: Diagnosis
and Management * Date/Time: Sunday, March 6 / 9:45 AM to 10:45 AM
* "Epicutaneous but Not Oral Immunotherapy Leads to Sustainable GATA-3
Hypermethylation and Foxp3 Hypomethylation in Peanut Sensitized Mice" will
be presented by Dr. Jorg Tost, Head of Laboratory for Epigenetics and
Environment (LEE), the National Genotyping Center, Genomics Institute/CEA.
To gain a fuller understanding of EPIT's mechanism of action, this animal
model studied the biochemical reaction of changes in gene expression with
EPIT compared to changes with oral immunotherapy (OIT). * Poster Session *
Session Number: 3206 * Poster Number: 422 * Session Title: Food Allergy:
Diagnosis and Management * Date/Time: Sunday, March 6 / 9:45 AM to 10:45 AM

* "Sustainability of Phenotype and Suppressive Activities of Tregs After
Discontinuation of EPIT but Not of OIT or SLIT in Peanut Sensitized Mice"
will be presented by Dr. Vincent Dioszeghy, DBV Technologies. With the
hypothesis that Tregs can help induce long-term tolerance, this experiment
measured Treg activity during treatment with EPIT, OIT and sublingual
immunotherapy (SLIT). Tregs induction was observed during OIT and SLIT, but
only EPIT-induced Tregs were maintained after the discontinuation of
treatment, suggesting that EPIT may induce tolerance. * Poster Session *
Session Number: 3206 * Poster Number: 415 * Session Title: Food Allergy:
Diagnosis and Management * Date/Time: Sunday, March 6 / 9:45 AM to 10:45 AM

* "Three Complementary Pathways Characterize the Suppressive Properties of
EPIT-Induced Tregs" will be presented by Dr. Benjamin Pelletier, DBV
Technologies. To better understand the mechanism of action in EPIT-induced
Tregs, the study analyzed the suppressive properties of these cells in
specific/ bystander conditions. * Poster Session * Session: 4210 * Poster
Number: 858 * Session Title: Immunotherapy, Rhinoconjunctivitis *
Date/Time: Monday, March 7 / 9:45 AM to 10:45 AM

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing
in prevalence. DBV Technologies, incorporated in France in 2002, has
developed a proprietary, patented technology for administering an allergen to
intact skin while avoiding transfer to the blood, and thus lowering the risk
of a systemic, allergic reaction in the event of accidental exposure. DBV
Technologies is focusing on food allergies, including milk and peanut, for
which there are currently no effective treatments. DBV Technologies has
designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The
clinical development program for Viaskin® Peanut has received Fast Track
designation and Breakthrough Therapy designation from the U.S. Food and Drug
Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of
American Depositary Shares (each representing one-...

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.